Recent Analysts’ Ratings Changes for Enovis (ENOV)

Enovis (NYSE: ENOV) has recently received a number of price target changes and ratings updates:

• 7/8/2026 – Enovis is now covered by BMO Capital Markets. They set an “outperform” rating and a $29.00 price target on the stock.
• 7/6/2026 – Enovis was given a new $32.00 price target by Evercore Inc.
• 7/6/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/30/2026 – Enovis was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/28/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/20/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/6/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/1/2026 – Enovis was downgraded by Zacks Research from “strong-buy” to “hold”.
• 5/22/2026 – Enovis had its “buy” rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.
• 5/10/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.

Insider Activity at Enovis

In related news, insider Oliver Engert acquired 1,200 shares of the stock in a transaction dated Thursday, June 11th. The stock was purchased at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the purchase, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders purchased 4,200 shares of company stock valued at $92,084 over the last three months. Corporate insiders own 2.90% of the company’s stock.

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.